[
  {
    "table_index": 1,
    "headers": [],
    "rows": [
      [
        "End Note"
      ],
      [
        "Procite"
      ],
      [
        "Reference Manager"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 2,
    "headers": [],
    "rows": [
      [
        "Imaging-based with or without blood-based for fibrosis or steatosis in adults"
      ],
      [
        "PICO 1",
        "In adult patients with CLD, including hepatocellular (HCV, HCV/HIV, HBV, HCV/HBV, HBV/HIV, NAFLD, ALD) or cholestatic (PSC, PBC) disorders, are imaging-based NILDA accurate in staging hepatic fibrosis (F0-1 vs. F2-4, F0-2 vs. F3-4, F0-3 vs. F4) using histopathology as the reference?"
      ],
      [
        "PICO 2",
        "In adult patients with CLD, including hepatocellular (HCV, HCV/HIV, HBV, HCV/HBV, HIV/HBV, NAFLD, ALD) or cholestatic (PSC, PBC) disorders, is one imaging-based NILDA more accurate than another in staging fibrosis (F0-1 vs. F2-4, F0-2 vs. F3-4, F0-3 vs. F4) using histopathology as the reference?"
      ],
      [
        "PICO 3",
        "In adult patients with CLD, including hepatocellular (HCV, HCV/HIV, HBV, HCV/HBV, HIV/HBV, NAFLD, ALD) or cholestatic (PSC, PBC) disorders, are imaging-based NILDA more accurate than blood-based NILDA?"
      ],
      [
        "PICO 4",
        "In adult patients with CLD, including hepatocellular (HCV, HCV/HIV, HBV, HCV/HBV, HBV/HIV, NAFLD, ALD) or cholestatic (PSC, PBC) disorders, is the combination of an imaging-based NILDA with a blood-based NILDA more accurate than a single test for staging fibrosis (F0-1 vs. F2-4, F0-2 vs. F3-4, F0-3 vs. F4) using histopathology as the reference?"
      ],
      [
        "PICO 5",
        "In adult patients with CLD, including hepatocellular (HCV, HCV/HIV, HBV, HCV/HBV, HIV/HBV, NAFLD, ALD) or cholestatic (PSC, PBC) disorders, do longitudinal imaging-based NILDA accurately predict progression or regression of fibrosis in its natural history or response to therapy relative to longitudinal hepatic histological evaluation as the reference?"
      ],
      [
        "PICO 6",
        "In adult patients with NAFLD, are imaging tests such as ultrasound, CT, or transient elastography (TE) with CAP accurate in grading hepatic steatosis (using histology, magnetic resonance [MR] spectroscopy, or MR-proton-density-fat-fraction [PDFF] as the reference)?"
      ],
      [
        "Imaging-based testing in children"
      ],
      [
        "PICO 7",
        "In children with CLD (HCV, HCV/HIV, HBV, HCV/HBV, HBV/HIV, BA, Alagille, α1AT, CFLD), are imaging-based tests accurate in staging hepatic fibrosis and steatosis?"
      ]
    ],
    "row_count": 9,
    "column_count": 1
  },
  {
    "table_index": 3,
    "headers": [],
    "rows": [
      [
        "1. Rating the quality of evidence"
      ],
      [
        "Study designRCTObservational",
        "Initial rating of quality of evidenceHighModerateLowVery low",
        "Rate down when:Risk of biasInconsistencyImprecisionIndirectnessPublication bias",
        "Rate up when:Large effect size (e.g., RR=0.5)Very large effect (e.g., RR=0.2)Dose response gradientAll plausible confounding would increase the association"
      ],
      [
        "2. Determinants of strength of a recommendationQuality of evidenceBalance of benefits and harmsPatient values and preferencesResources and costs"
      ],
      [
        "3. Implications of the strength of a recommendationStrongPopulation: Most people in this situation would want the recommended course of action and only a small proportion would not.Health care workers: Most people should receive the recommended course of action.Policy makers: The recommendation can be adopted as policy in most situations.ConditionalPopulation: The majority of people in this situation would want the recommended course of action, but many would not.Health care workers: Be prepared to help patients make a decision that is consistent with their values using decision aids and shared decision making.Policy makers: There is a need for substantial debate and involvement of stakeholders."
      ]
    ],
    "row_count": 4,
    "column_count": 1
  },
  {
    "table_index": 4,
    "headers": [
      "",
      "Fibrosis stage"
    ],
    "rows": [
      [
        "",
        "",
        "",
        "Significant fibrosis",
        "",
        ""
      ],
      [
        "",
        "",
        "",
        "",
        "Advanced fibrosis",
        ""
      ],
      [
        "",
        "",
        "",
        "",
        "",
        "Cirrhosis"
      ],
      [
        "Scheuer/Batts-Ludwig (Viral and autoimmune hepatitis)13,14",
        "No fibrosis",
        "Enlarged, fibrotic portal tracts",
        "Periportal or portal-portal septa but intact architecture",
        "Fibrosis with architectural distortion but no obvious cirrhosis",
        "Probable or definite cirrhosis"
      ],
      [
        "Knodell (Viral and autoimmune hepatitis)15",
        "No fibrosis",
        "Fibrous portal expansion",
        "N/A",
        "Bridging fibrosis",
        "Cirrhosis"
      ],
      [
        "Ishak (Various etiologies)16",
        "0: No fibrosis",
        "1: Fibrous expansion of some portal areas, with or without short fibrous septa",
        "2: Fibrous expansion of most portal areas, with or without short fibrous septa3: Fibrous expansion of most portal areas with occasional portal to portal bridging",
        "4: Fibrous expansion of portal areas with marked bridging5: Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis)",
        "6: Cirrhosis (probable or definite)"
      ],
      [
        "METAVIR (Various etiologies)17",
        "No fibrosis",
        "Stellate enlargement of portal tract but without septa formation",
        "Enlargement of portal tract with rare septa formation",
        "Numerous septa without cirrhosis",
        "Cirrhosis"
      ],
      [
        "Ludwig (PBC and PSC)18",
        "N/A",
        "N/A",
        "N/A",
        "Bridging fibrosis",
        "Cirrhosis"
      ],
      [
        "Alcohol-associated liver disease (alcohol hepatitis histological score)19",
        "No fibrosis or portal fibrosis",
        "Expansive periportal fibrosis",
        "Bridging fibrosis",
        "Cirrhosis",
        ""
      ],
      [
        "Brunt-Kleiner (NAFLD)20,21",
        "No fibrosis",
        "1A: delicate perisinusoidal 1B: dense perisinusoidal 1C: portal-only fibrosis",
        "Perisinusoidal and portal/periportal fibrosis",
        "Bridging fibrosis",
        "Cirrhosis"
      ]
    ],
    "row_count": 10,
    "column_count": 2
  },
  {
    "table_index": 5,
    "headers": [
      "Degree of steatosis"
    ],
    "rows": [
      [
        "0 (Normal or minimal)",
        "1 (Mild)",
        "2 (Moderate)",
        "3 (Severe)"
      ],
      [
        "<5%",
        "5%-33%",
        "34%-66%",
        ">66%"
      ]
    ],
    "row_count": 2,
    "column_count": 1
  },
  {
    "table_index": 6,
    "headers": [
      "Diagnostic index",
      "Calculation",
      "Comments"
    ],
    "rows": [
      [
        "Sensitivity",
        "TP/(TP+FN)",
        "Not dependent on population. Correctly detect patients who are ill who have the condition. High sensitivity helps rule out the disease (few false negatives)."
      ],
      [
        "Specificity",
        "TN/(TN+FP)",
        "Not dependent on population. A high specificity means a test is useful for ruling in disease. High specificity helps ruling in disease (few false positives)."
      ],
      [
        "Accuracy",
        "(TP+TN)/(P+N)",
        ""
      ],
      [
        "PPV",
        "TP/(TP+FP)",
        "The probability that a person with a positive test indeed has the disease or condition of interest. Used to “rule in” disease. Affected by the prevalence of the disease in the population."
      ],
      [
        "NPV",
        "TN/(TN+FN)",
        "The probability that a person with a negative test does NOT have the disease or condition of interest. Important for screening studies to not miss disease. Affected by the prevalence of the disease in the population."
      ],
      [
        "Positive LR",
        "TP/(TP+FN)FP/(FP+TN)",
        "Depends on patient population. Positive LR above 10 suggests strong test"
      ],
      [
        "Negative LR",
        "FN/(TP+FN)TN/(FP+TN)",
        "Depends on patient population. Negative LR below 0.1 suggests strong diagnostic evidence"
      ],
      [
        "DOR",
        "Positive LR/negative LR",
        "The ratio of odds of positivity of those with disease relative to odds of positivity in those without disease"
      ],
      [
        "Area under the receiver operating characteristic curve (AUC)",
        "Graph values of test performance from 0 (a perfectly inaccurate test) to 1 (a perfect test). Plots the diagnostic ability of a binary classifier system as its discrimination threshold is varied.",
        "Summarizes the overall diagnostic accuracy of a test. In general, an AUC of 0.5 suggests no discrimination (i.e., ability to diagnose patients with and without the disease or condition based on the test), 0.7 to 0.8 is considered acceptable, 0.8 to 0.9 is considered excellent, and more than 0.9 is considered outstanding"
      ]
    ],
    "row_count": 9,
    "column_count": 3
  },
  {
    "table_index": 7,
    "headers": [
      "Method",
      "Availability",
      "Cost",
      "Evidence",
      "ROI size",
      "ROI placement",
      "Failure rate",
      "Reasons for failure",
      "Units",
      "Brand/vendor"
    ],
    "rows": [
      [
        "TE",
        "Widespread in hepatology offices",
        "Low",
        "Well validated",
        "Small",
        "Restricted - no guidance",
        "<5%-15%",
        "High BMI (M probe) ascites",
        "Young’s modulus (kPa)",
        "Fibroscan, Echosens, Paris"
      ],
      [
        "ARFI methods",
        "Moderate",
        "Low",
        "Moderate validation in single etiology CLD with histology as reference standard",
        "Small (pSWE)Medium (2D-SWE)",
        "Flexible up to 8-cm depth with US guidance",
        "<5%-15%",
        "High BMI",
        "SWE --Young’s modulus (kPa)pSWE --Wave speed (m/s)",
        "pSWE: Virtual Touch Quantification [a type of ARFI] by Siemens Healthineers, Erlangen, Germany; and Elast-PQ [EPIQ7 ultrasound], Philips Healthcare, Bothell, WA2D-SWE: Virtual Touch Imaging Quantification by Siemens Healthineers, Erlangen, Germany; SWE by Aixplorer, Supersonic Imagine, Hologic, Inc., France; ElastQ, Philips Healthcare, Netherlands; Acoustic Structure Quantification by Canon; 2D-SWE LOGIQ E9 ShearWave Elastography, GE Healthcare, WI; Hitachi Medical Systems, Japan; Esaote SpA, Genoa, Italy; and Samsung Medison Co., Seoul, Korea"
      ],
      [
        "MRE",
        "Limited",
        "High",
        "Limited validation in single etiology CLD with histology as reference standard",
        "Large",
        "Whole organ coverage (within confidence maps)",
        "<5%",
        "Liver iron deposition, Large ascites, Very high BMI, 3T (for 2D GRE)",
        "Shear modulus (kPa)",
        "Resoundant (available on GE Healthcare, Siemens Healthineers, Philips)"
      ]
    ],
    "row_count": 3,
    "column_count": 10
  },
  {
    "table_index": 8,
    "headers": [
      "Clinical condition",
      "Tools affected",
      "Comments"
    ],
    "rows": [
      [
        "Obesity32,35–39",
        "LSM",
        "Although an XL probe can remediate TE-LSM failure in most cases with SCD≥25 mm, extreme obesity (BMI≥40 kg/m2) can result in TE-LSM failure.Depending on body frame, extreme obesity can also affect transmission of mechanical wave, leading to MRE failure, but this is far less common than TE failures.SWE acoustic signal transmission can also be affected by obesity, resulting in failure."
      ],
      [
        "Narrow intercostal space",
        "TE",
        "If not corrected by repositioning, leads to failure or falsely elevated estimation"
      ],
      [
        "Ascites36",
        "LSMTE affected more that SWE, with MR being the least affected",
        "Affects transmission of vibration and mechanical signals, leading to failureAlthough SWE and MR are relatively insensitive to small amounts of ascites, large amounts can lead to failure."
      ],
      [
        "Splenectomy",
        "APRIFIB-4FibroindexFibroMeterNFS",
        "Because these tools use platelets as a biomarker of PHTN, attenuated thrombocytopenia from splenectomy gives a falsely lower estimation.Splenomegaly as an imaging sign of PHTN cannot be assessed."
      ],
      [
        "Thrombocytopenia (not related to PHTN)",
        "APRIFIB-4FibroindexFibroMeterNFS",
        "Because these tools use platelets as a biomarker of PHTN, thrombocytopenia from other conditions gives a falsely higher estimation."
      ],
      [
        "Iron overload40",
        "MRE",
        "Affects T2 signaling leading to failure"
      ],
      [
        "Steatosis41–43",
        "TE",
        "Although its clinical impact is unclear, moderate to severe steatosis causes TE-LSM to overestimate fibrosis."
      ],
      [
        "Active alcohol use44",
        "FibroTestHepascore",
        "Increases GGT, leading to falsely elevated estimation"
      ],
      [
        "Hepatic venous outflow tract obstruction, sinusoidal obstruction syndrome, hepatic congestion of cardiac/pulmonary vascular origin45",
        "LSM",
        "Retrograde vascular congestion results in increased stiffness of hepatic parenchyma and falsely elevated estimation of fibrosis"
      ],
      [
        "Obstructive cholestasis46",
        "LSM",
        "Large bile duct obstruction results in increased stiffness of hepatic parenchyma and falsely elevated estimation of fibrosis"
      ],
      [
        "Hepatic infiltration47",
        "LSM",
        "Amyloid or tumoral infiltration results in increased stiffness of hepatic parenchyma and falsely elevated estimation of fibrosis"
      ],
      [
        "Elevated ALT and/or AST (inflammatory hepatitis)33,44,48",
        "APRIFIB-4FibroindexFibroMeterNAFLD fibrosis scoreLSM",
        "Elevated aminotransferases occurring in relation to acute or acute-on-chronic hepatitis lead to a falsely elevated estimation of fibrosis."
      ],
      [
        "Chronic kidney disease49–51",
        "FibroindexAPRIFIB-4FibroMeterTE-LSM",
        "Elevated urea levels can result in falsely lower estimation.Patients undergoing hemodialysis tend to have lower ALT and AST levels, resulting in falsely lower estimation.Hemofiltration can result in lower stiffness in patients with baseline fluid overload."
      ],
      [
        "Malnutrition",
        "NAFLD fibrosis score",
        "Albumin reduction that is disproportionate to liver dysfunction results in falsely elevated estimation."
      ],
      [
        "Inflammatory condition",
        "FibroTestFibroindexHepascoreFibroMeter",
        "Can result in increased α2-macroglobulin levels and falsely elevated Fibrotest, increased γ-globulin, and falsely elevated Fibroindex"
      ],
      [
        "Hemolysis",
        "Fibrotest",
        "Decreases haptoglobin levels and increases total bilirubin, leading to falsely elevated estimation"
      ],
      [
        "Gilbert syndrome and other cholestatic diseases",
        "FibroTestHepascore",
        "Can result in increased total bilirubin and falsely elevated estimation"
      ],
      [
        "Postprandial52",
        "LSMNFS",
        "Liver stiffness increases up to 26% have been described for TE-LSM 2 hours after a meal. Other methods of assessing LSM are also affected by recent meals.A rise in postprandial glucose (>110 mg/dL) falsely elevates NAFLD fibrosis score."
      ],
      [
        "Gastrectomy53",
        "FibrospectHepascoreELF",
        "Increases hyaluronic acid, resulting in falsely elevated estimation"
      ],
      [
        "Extra-hepatic fibrosing conditions54",
        "FibroMeterFibrospectELF",
        "Conditions such as interstitial lung disease can increase collagen turnover markers, resulting in elevated estimation"
      ],
      [
        "Acute sickle cell crisis55",
        "FibrotestTE",
        "Related to hemolysis (as above)Acute vaso-occlusive crisis increases liver stiffness."
      ],
      [
        "Critically ill56",
        "LSM",
        "Deceased liver donors in the ICU show elevated liver stiffness, potentially related to fluid overload and elevated aminotransferases."
      ]
    ],
    "row_count": 22,
    "column_count": 3
  },
  {
    "table_index": 9,
    "headers": [
      "Clinical condition",
      "Tools affected",
      "Comments"
    ],
    "rows": [
      [
        "Obesity57",
        "TE-CAP",
        "Readings need to be corrected deducting or adding 4.4 dB/m per BMI above or below 25 kg/m2(within the 20-30 range)."
      ],
      [
        "Diabetes mellitus57",
        "TE-CAP",
        "Readings need to be corrected by deducting 10 dB/m in patients with diabetes mellitus."
      ],
      [
        "NAFLD257",
        "TE-CAP",
        "Readings need to be corrected by deducting 10 dB/m in patients with known NAFLD."
      ]
    ],
    "row_count": 3,
    "column_count": 3
  },
  {
    "table_index": 10,
    "headers": [
      "Disease",
      "Fibrosis stage",
      "TE cutoff",
      "pSWE/2D-SWE cutoffa",
      "References",
      "POR (95% CI)"
    ],
    "rows": [
      [
        "HCV",
        "F0-1 vs. F2-4",
        "6.5-6.7 kPa",
        "1.2 m/s (pSWE)",
        "107,108",
        "2.67 (0.40-17.66)"
      ],
      [
        "",
        "F0-2 vs. F3-4",
        "9.6 kPa",
        "1.6 m/s (pSWE)",
        "100",
        "2.20 (0.28-17.04)"
      ],
      [
        "",
        "F0-3 vs. F4",
        "12.2-13.1 kPa",
        "1.8-2 m/s (pSWE)",
        "100,107",
        "2.18 (0.56-8.49)"
      ],
      [
        "HBV",
        "F0-1 vs. F2-4",
        "6.9-7.3 kPa",
        "7.1 kPa (2D-SWE)",
        "102,104",
        "0.40 (0.16-1.01)"
      ],
      [
        "",
        "F0-3 vs. F4",
        "10.6-11.2 kPa",
        "11.3 kPa (2D-SWE)",
        "104",
        "0.71 (0.10-5.24)"
      ],
      [
        "",
        "",
        "",
        "1.75 m/s (pSWE)",
        "105",
        "0.71 (0.20-2.47)"
      ],
      [
        "NAFLD",
        "F0-3 vs. F4",
        "16.1 kPa",
        "2 m/s (pSWE)",
        "37",
        "2.36 (0.86-6.48)"
      ]
    ],
    "row_count": 7,
    "column_count": 6
  },
  {
    "table_index": 11,
    "headers": [
      "References",
      "Study cohort",
      "Clinical variables",
      "Indirect markers",
      "Direct markers",
      "Model algorithm"
    ],
    "rows": [
      [
        "APRI,120",
        "HCV",
        "—",
        "AST, platelets",
        "—",
        "[(AST level/ULN)/platelet count (109/L)]×100"
      ],
      [
        "Fibrosis-4 Index(FIB-4),121",
        "HIV-HCV",
        "Age",
        "AST, ALT, platelets",
        "—",
        "Age (y)×AST (U/L)Platelet count (109/L)×√ALT (U/L)"
      ],
      [
        "NAFLD Fibrosis Score (NFS),122",
        "NAFLD",
        "Age, BMI, IFG/diabetes",
        "AST, ALT, platelets, albumin",
        "—",
        "−1.675+(0.037×age)+(0.094×BMI)+1.13×IFG/diabetes (yes=1, no=0)+0.99×(AST/ALT ratio) − (0.013×platelets) − (0.66×albumin)"
      ],
      [
        "Easy Liver Fibrosis Test (eLIFT),123",
        "Mixed",
        "Age, Sex",
        "GGT, AST, platelets, prothrombin index",
        "—",
        "Component weighted scores (0-4)"
      ],
      [
        "FibroTest,124",
        "HCV",
        "—",
        "α2M, GGT, total bilirubin, haptoglobin, ApoA-I1",
        "—",
        "Proprietary"
      ],
      [
        "ELF,125",
        "Mixed",
        "Age",
        "—",
        "HA, PIIINP, TIMP-1",
        "Proprietary"
      ],
      [
        "FibroSpect II,126",
        "HCV",
        "—",
        "α2M",
        "HA, TIMP-1",
        "Proprietary"
      ],
      [
        "HepaScore,127",
        "HCV",
        "Age, Sex",
        "Total bilirubin, α2M, GGT",
        "HA",
        "Proprietary"
      ],
      [
        "FibroMeter,128",
        "Mixed",
        "Age",
        "Platelets, prothrombin index, urea, AST, α2M",
        "HA",
        "Proprietary"
      ]
    ],
    "row_count": 9,
    "column_count": 6
  },
  {
    "table_index": 12,
    "headers": [
      "Disease",
      "Fibrosis stage",
      "Imaging testa(cutoff)",
      "Blood test (cutoff)",
      "POR (95% CI)",
      "References"
    ],
    "rows": [
      [
        "HCV",
        "F0-1 vs F2-4",
        "TE7 (6.5 to 7.4) kPa",
        "APRI0.5 (0.37 to 0.67)",
        "2.31 (0.39-13.54)",
        "108,129–131"
      ],
      [
        "",
        "",
        "",
        "APRI1.5",
        "2.05 (0.49-8.58)",
        "132"
      ],
      [
        "",
        "",
        "",
        "APRI1 (0.75 to 1.1)",
        "1.41 (0.51-3.94)",
        "133,134"
      ],
      [
        "",
        "",
        "",
        "FIB-41.05",
        "8.48(4.88-14.76)",
        "129"
      ],
      [
        "",
        "",
        "",
        "FIB-41.45 (1.29 to 1.47)",
        "2.85 (0.84-9.61)",
        "108,133"
      ],
      [
        "",
        "",
        "",
        "FIB-42.1",
        "0.05 (0.001-26.71)",
        "130"
      ],
      [
        "",
        "",
        "pSWE1.22 m/s",
        "FIB-41.45 (1.26 to 1.53)",
        "0.59 (0.21-1.65)",
        "108,133"
      ],
      [
        "",
        "",
        "",
        "APRI0.67",
        "0.70 (0.20-2.42)",
        "108"
      ],
      [
        "",
        "",
        "",
        "APRI0.75",
        "0.28 (0.02-3.53)",
        "133"
      ],
      [
        "",
        "F0-2 vs F3-4",
        "TE10 (9.5 to 10.4) kPa",
        "APRI0.62",
        "11.62(1.58-85.47)",
        "135,136"
      ],
      [
        "",
        "",
        "",
        "APRI1.13",
        "1.92 (0.56-6.62)",
        "134"
      ],
      [
        "",
        "",
        "",
        "FIB-41.45",
        "2.58(1.50-4.43)",
        "123"
      ],
      [
        "",
        "",
        "",
        "FIB-41.87",
        "4.77 (0.48-47.85)",
        "135"
      ],
      [
        "",
        "",
        "",
        "FIB-43.25",
        "51.44(22.53-117.48)",
        "137"
      ],
      [
        "",
        "",
        "pSWE1.7 (1.61 to 1.84) m/s",
        "FIB-43.25 (3.21 to 3.97)",
        "1.47 (0.15-14.33)",
        "138,139"
      ],
      [
        "",
        "",
        "",
        "APRI0.62",
        "11.58(2.37-56.53)",
        "140"
      ],
      [
        "",
        "F0-3 vs F4",
        "pSWE2 (1.73 to 2.48) m/s",
        "APRI0.5 (0.25 to 0.75)",
        "0.71 (0.12-4.16)",
        "140"
      ],
      [
        "",
        "",
        "",
        "APRI1.5 (1.27 to 1.73)",
        "2.34 (0.04-140.56)",
        "133,138"
      ],
      [
        "",
        "",
        "",
        "FIB-44",
        "0.05 (0.001-29.81)",
        "133"
      ],
      [
        "",
        "",
        "TE11 (10 to 11.9) kPa",
        "APRI2",
        "0.83 (0.002-441)",
        "141"
      ],
      [
        "",
        "",
        "TE13 (12 to 14) kPa",
        "APRI1 (0.76 to 1.2)",
        "31.99(4.54-225.58)",
        "129"
      ],
      [
        "",
        "",
        "",
        "APRI1.5 (1.27 to 1.73)",
        "2.65 (0.32-22.12)",
        "130,133"
      ],
      [
        "",
        "",
        "",
        "APRI2 (2 to 4.3)",
        "10.33(3.76-28.37)",
        "108,132"
      ],
      [
        "",
        "",
        "",
        "FIB-41.45 (0.8 to 2)",
        "7.09(1.94-25.82)",
        "129,135"
      ],
      [
        "",
        "",
        "",
        "FIB-42.31",
        "24.48(1.87-320.86)",
        "130"
      ],
      [
        "",
        "",
        "",
        "FIB-44",
        "0.11 (0.001-76.52)",
        "133"
      ],
      [
        "",
        "",
        "",
        "FibroSure/FibroTest0.75 (0.7 to 0.81)",
        "2.98(1.04-8.55)",
        "142"
      ],
      [
        "HCV/HIV",
        "F0-1 vs F2-4",
        "TE7 (6.5 to7.4) kPa",
        "APRI0.5",
        "4.57(1.81-11.56)",
        "143,144"
      ],
      [
        "",
        "",
        "",
        "APRI1.1",
        "1.30 (0.34-5.07)",
        "144"
      ],
      [
        "",
        "",
        "",
        "APRI1.5 (1.3 to 1.54)",
        "2.38 (0.86-6.60)",
        "143,144"
      ],
      [
        "",
        "",
        "",
        "FIB-41.45 (1.21 to 1.65)",
        "3.00 (0.83-10.82)",
        "144"
      ],
      [
        "",
        "",
        "",
        "FibroSure/FibroTest0.48 (0.4 to 0.5)",
        "0.85 (0.31-2.39)",
        "143,144"
      ],
      [
        "HBV",
        "F0-1 vs F2-4",
        "pSWE1.2 (0.95 to 1.26) m/s",
        "APRI0.36",
        "0.99 (0.140-7.09)",
        "145"
      ],
      [
        "",
        "",
        "",
        "APRI1",
        "1.46 (0.17-12.66)",
        "145"
      ],
      [
        "",
        "",
        "",
        "FIB-40.63",
        "3.43 (0.39-29.63)",
        "145"
      ],
      [
        "",
        "",
        "",
        "FIB-42.2",
        "0.80 (0.10-6.56)",
        "145"
      ],
      [
        "",
        "",
        "TE7 (6.5 to7.4) kPa",
        "APRI0.5 (0.17 to 0.67)",
        "5.01 (0.98-25.58)",
        "146"
      ],
      [
        "",
        "",
        "",
        "FIB-43.25 (2.71 to 4.9)",
        "0.86 (0.10-7.82)",
        "147"
      ],
      [
        "",
        "F0-2 vs F3-4",
        "TE8 (7.6 to 8.4) kPa",
        "FIB-41.45",
        "16.73(3.76-74.47)",
        "148"
      ],
      [
        "",
        "",
        "",
        "FIB-43.25",
        "7.59 (0.90-63.71)",
        "148"
      ],
      [
        "",
        "F0-3 vs F4",
        "pSWE1.8 (1.74 to 1.98) m/s",
        "APRI0.5",
        "19.95(1.54-258.17)",
        "149"
      ],
      [
        "",
        "",
        "",
        "FIB-42.83",
        "34.03(3.41-339.16)",
        "149"
      ],
      [
        "",
        "",
        "TE11 (10 to 11.9) kPa",
        "APRI0.5",
        "3.03(1.17-7.85)",
        "150"
      ],
      [
        "",
        "",
        "",
        "APRI0.8",
        "9.25(4.99-17.13)",
        "151"
      ],
      [
        "",
        "",
        "",
        "APRI2",
        "0.65 (0.001-344.43)",
        "141,152"
      ],
      [
        "",
        "",
        "",
        "FIB-41.45 (0.8 to 1.94)",
        "3.09(1.65-5.79)",
        "150,151"
      ],
      [
        "NAFLD",
        "F0-1 vs F2-4",
        "TE7 (6.5 to 7.3) kPa",
        "APRI0.5",
        "0.94 (0.27-3.30)",
        "153"
      ],
      [
        "",
        "F0-2 vs F3-4",
        "pSWE1.55 (1.4 to 1.59) m/s",
        "APRI0.5 (0.43 to 0.71)",
        "2.28 (0.81-6.42)",
        "154"
      ],
      [
        "",
        "",
        "TE10 (9.5 to 10.4) kPa",
        "APRI0.5",
        "1.46 (0.64-3.37)",
        "155"
      ],
      [
        "",
        "",
        "",
        "APRI1",
        "4.35 (0.39-48.46)",
        "156"
      ],
      [
        "",
        "",
        "",
        "APRI1.5",
        "1.75 (0.26-11.91)",
        "155,157"
      ],
      [
        "",
        "",
        "",
        "FIB-41.3 (0.85 to 1.3)",
        "1.57(1.02-2.43)",
        "155,158"
      ],
      [
        "",
        "",
        "",
        "FIB-42.67 (2.09 to 2.67)",
        "1.27 (0.69-2.34)",
        "155,156,158"
      ],
      [
        "",
        "",
        "",
        "FIB-43.25",
        "3.32 (0.24-45.54)",
        "159"
      ],
      [
        "",
        "",
        "MRE3.7 (3.6 to 3.8) kPa",
        "APRI1",
        "9.01 (0.95-85.67)",
        "160"
      ],
      [
        "",
        "",
        "",
        "FIB-41.3",
        "6.16 (0.75-50.39)",
        "160"
      ],
      [
        "",
        "",
        "",
        "FIB-42.67",
        "5.98 (0.55-65.38)",
        "160"
      ],
      [
        "ALD",
        "F0-2 vs F3-4",
        "2D-SWE16.1 kPa",
        "APRI1",
        "25.35(7.68-83.62)",
        "161"
      ],
      [
        "",
        "",
        "",
        "FIB-43.25",
        "10.35(3.13-34.23)",
        "161"
      ],
      [
        "",
        "",
        "TE15 kPa",
        "APRI1",
        "16.79(5.56-50.76)",
        "161"
      ],
      [
        "",
        "",
        "",
        "FIB-43.25",
        "6.86(2.26-20.78)",
        "161"
      ],
      [
        "",
        "F0-3 vs F4",
        "TE15 kPa",
        "FibroSure/FibroTest0.75",
        "5.00(1.54-16.25)",
        "162"
      ]
    ],
    "row_count": 62,
    "column_count": 6
  },
  {
    "table_index": 13,
    "headers": [
      "References",
      "No. of biopsies (F2-4 prevalence)",
      "Elastography type and optimal LSM",
      "Single test AUC",
      "*Combined test AUC",
      "Comments"
    ],
    "rows": [
      [
        "HCV172",
        "183 (74%)",
        "TE-LSM 7.1 kPa",
        "TE-LSM=0.83FT=0.85APRI=0.78",
        "TE-LSM+APRI=0.84TE-LSM+FT=0.88TE-LSM+FT+APRI=0.88",
        "Agreement FT and TE-LSM 77%; biopsy confirmed F2-3=84%"
      ],
      [
        "HCV173",
        "729 (58.4%)",
        "TE-LSM NA",
        "TE-LSM=0.79FM=0.81",
        "TE-LSM+FM=0.85",
        "Improved AUC for combination compared to FM or TE-LSM alone"
      ],
      [
        "HCV141",
        "382 (47%)",
        "TE-LSM 5.2 kPa",
        "TE-LSM=0.82FM=0.83FT=0.81APRI=0.78ELF= 0.78HS= 0.82FIB-4= 0.78",
        "Not provided",
        "Accuracy increased from 70%-73% (single test) to 78%-82% for TE-LSM combination"
      ],
      [
        "HBV96",
        "81 (63%)",
        "ARFI 1.295 m/sTE-LSM 8.3 kPa",
        "ARFI=0.76TE-LSM=0.75Forns=0.73",
        "AccuracyARFI+Forns=90.7%TE-LSM+Forns=76.1%",
        "Discordance 24%-34% for synchronous tests"
      ],
      [
        "HBV98",
        "92 (72%)",
        "ARFI 1.27 m/sTE-LSM 6.6 kPa",
        "ARFI=0.91TE-LSM=0.87APRI=0.79",
        "ARFI+TE-LSM+APRI=0.92",
        "No difference for linear combination over elastography alone"
      ],
      [
        "HBV174",
        "70 (34%)",
        "TE-LSM 7.5 kPa",
        "TE-LSM=0.87Blood markers=0.86",
        "TE-LSM+markers=0.86",
        "No difference for combination compared with TE-LSM or blood-marker panel (HA, PIIINP, type IV collagen, ALT, AST) alone"
      ],
      [
        "HBV145",
        "101 (55%)",
        "ARFI 0.97 and 1.36 m/s",
        "ARFI=0.70APRI=0.62FIB-4=0.64",
        "ARFI+APRI+FIB-4—not provided",
        "New thresholds for APRI/FIB-4. Combination at upper/lower cutoffs reduced biopsy for F2-4 in 44%"
      ],
      [
        "HIV-HCV141",
        "116 (41%)",
        "TE-LSM 7.1 kPa",
        "TE-LSM=0.87FT=0.85APRI=0.71",
        "AccuracyTE-LSM+FT=61.2%",
        "Synchronous algorithm. Lower correct classification (61.2%) compared with TE-LSM (80.2%) and FT (73.3%) alone"
      ],
      [
        "HIV-HBV175",
        "59 (61%)",
        "TE-LSM 5.9 kPa",
        "TE-LSM=0.85FT-Accuracy 81%",
        "Sequential TE-LSM → FT=not provided",
        "Most receiving cART and 68% with normal ALTSequential TE-LSM and FT biopsy required in 33% discordant cases"
      ],
      [
        "NAFLD176",
        "215 (32%)",
        "TE-LSM 5.8 kPa",
        "TE-LSM=0.85FM=0.77APRI=0.65FIB-4=0.65NFS=0.65",
        "FM-TE-LSM=0.85",
        "Proprietary algorithm combining FM-TE-LSM. High NPV for TE-LSMSequential application for FM after TE-LSM increased PPV 71% to 84%"
      ],
      [
        "PBC177",
        "114 (84%)",
        "TE-LSM 5.9 kPa",
        "TE-LSM=0.89APRI=0.66FIB-4=0.59Forns=0.73",
        "TE-LSM+APRI=0.89TE-LSM+FIB-4=0.89TE-LSM+Forns=0.89",
        "No increase in diagnostic accuracy for combination compared to TE-LSM alone"
      ],
      [
        "Mixed CLD, 2009178CHC/CHB=49%ALD=27%",
        "390 (74%)",
        "TE-LSM NA",
        "TE-LSM=0.87FM=0.83",
        "TE-LSM+FM=0.89",
        "Synchronous algorithm; higher AUC for combined test"
      ],
      [
        "Mixed CLD179CHC/CHB=40%HIV-HCV=22%, NAFLD=13%ALD=11%",
        "1968 (58%)",
        "TE-LSM/A",
        "TE-LSM=0.79-0.92FM=0.70-0.85",
        "TE-LSM+FM=0.84-0.90",
        "Higher AUC for combined tests for CHC"
      ]
    ],
    "row_count": 13,
    "column_count": 6
  },
  {
    "table_index": 14,
    "headers": [
      "References",
      "No. of biopsies (F2-4 prevalence)",
      "Elastography type and optimal LSM",
      "Single test AUC",
      "*Combined test AUC",
      "Comments"
    ],
    "rows": [
      [
        "HCV172",
        "183 (45%)",
        "TE-LSM 9.5 kPa",
        "TE-LSM=0.90FT=0.90APRI=0.84",
        "TE-LSM+APRI=0.91TE-LSM+FT=0.95TE-LSM+FT+APRI=0.95",
        "Agreement FT and TE-LSM 70%Biopsy confirmed F3-4 in 95%"
      ],
      [
        "HCV173",
        "729 (33%)",
        "N/A",
        "TE-LSM=0.85FM=0.83",
        "TE-LSM+FM=0.87",
        "Improved AUC for combination compared with FM or TE-LSM alone"
      ],
      [
        "HBV180",
        "238 (36%)",
        "TE-LSM 9-12 kPa (normal-elevated ALT)",
        "TE-LSM=0.80-0.88Forns=0.70-0.72",
        "TE-LSM+Forns—Not provided",
        "Results provided for training and validation cohorts; new thresholds for Forns (5.2 and 8.4)Reduced proportion of incorrect diagnosis for LSM-Forns (3%-5%) than LSM alone (3%-15%)"
      ],
      [
        "HBV181",
        "323 (40%)",
        "TE-LSM 9-12 kPa (normal-elevated ALT)",
        "TE-LSM=0.73-0.83ELF=0.68-0.69",
        "TE-LSM+ELF—Not provided",
        "Results provided for training and validation cohorts; new thresholds for ELF 8.4 (exclusion) and 10.8 (confirmatory); similar performance for ELF-LSM and LSM alone"
      ],
      [
        "HBV174",
        "222 (64%)",
        "TE-LSM 7.5/8-10.5/11 kPa (normal-elevated ALT)",
        "TE-LSM=0.89ELF=0.70",
        "TE-LSM+ELF—Paired or sequential AUC not provided",
        "Sequential TE-LSM-ELF better than concurrent use for avoiding biopsy (69%-72% vs 42%-59%)"
      ],
      [
        "HIV-HBV175",
        "59 (33%)",
        "TE-LSM 7.6 kPa",
        "TE-LSM=0.85FT-Accuracy 81%",
        "TE-LSM+FT—Not provided",
        "Most receiving cART and 68% with normal ALT; sequential TE-LSM and FTBiopsy required in 29% discordant cases"
      ],
      [
        "HIV-HBV165",
        "63 (21%)",
        "TE-LSM 7.8 kPa",
        "TE-LSM=0.78APRI=0.68FIB-4=0.63",
        "TE-LSM+FT or APRI—Not provided",
        "No discriminatory benefit for TE-LSM+APRI or FIB-4New optimal thresholds for APRI=0.42, and FIB-4=1.76"
      ],
      [
        "NAFLD182",
        "321 (22%)",
        "TE-LSM 7.9 and 9.6 kPa",
        "TE-LSM=0.85-0.86FIB-4=0.70-0.79NFS=0.73-0.80",
        "TE-LSM+FIB-4=0.85-0.89TE-LSM+NFS=0.84-0.88",
        "Included training and validation cohortsTE-LSM+NFS best diagnostic performance, but uncertainty in 41%-48%"
      ],
      [
        "NAFLD176",
        "215 (20%)",
        "TE-LSM 7.9 kPa",
        "TE-LSM=0.94FM=0.77APRI=0.72FIB-4=0.70NFS=0.65",
        "FM-TE-LSM=0.90",
        "Proprietary algorithm combining FM-TE-LSM high NPV for TE0-LSM-sequential application for TE-LSM-FM after TE-LSM increased PPV 61% to 89%"
      ],
      [
        "NAFLD158",
        "761 (31%)",
        "TE-LSM 7.9 and 9.6 kPa",
        "TE-LSM=0.86FIB-4=0.79NFS=0.77APRI=0.72",
        "AccuracyTE-LSM+NFS=39%TE-LSM+ FIB-4=43%Sequential NFS or FIB-4 → TE-LSM=70%",
        "Paired combination had lower accuracy and 54%-58% uncertaintyBetter accuracy and lower uncertainty (19%-20%) for sequential tests"
      ],
      [
        "NAFLD78",
        "3202 (71%)",
        "TE-LSM 9.9 and 11.4 kPa (n=1765)",
        "TE-LSM=0.80ELF=0.80FIB-4=0.78NFS=0.74",
        "Accuracy or AUC not provided for paired or sequential tests",
        "Paired combination of TE-LSM+NFS or FIB-4 had 4%-5% misclassified but increased indeterminates (IND) (64%-65%)Sequential FIB-4 followed by TE-LSM reduced IND to 20% but higher misclassified rate (20%)"
      ],
      [
        "NAFLD183",
        "938 (41%)",
        "TE-LSM 7.9 and 9.6 kPa",
        "TE-LSM=0.84NFS=0.72FIB-4=0.76FT=0.74HS=0.76FM=0.79",
        "Accuracy for Sequential testsFIB-4 → FMTE-LSM=88%TE-LSM → FMTE-LSM=90%NFS → TE-LSM=80%FIB-4 → TE-LSM=80%",
        "Training and validation cohorts. FMTE-LSMhad higher accuracy and sensitivity as second-line test compared with TE-LSM alone"
      ],
      [
        "NAFLD184",
        "278 (28%)",
        "TE-LSM 9.9 kPa",
        "TE-LSM=0.89APRI=0.79FIB-4=0.83NFS=0.80",
        "FIB-4+TE-LSM=0.92NFS+TE-LSM=0.91APRI +TE-LSM=0.90",
        "Regression index of TE-LSM with various blood-based markers improved diagnostic accuracy"
      ],
      [
        "NAFLD185",
        "224 (36%)",
        "TE-LSM 11.45 kPa",
        "TE-LSM=0.84ELF=0.81FIB-4=0.78",
        "AccuracyCombined ELF+TE-LSM=79%Sequential ELF+TE-LSM=75%",
        "Variable cohort-specific new ELF and LSM thresholds for optimal performance. No difference in accuracy for combined vs. sequential use, or compared with single tests"
      ],
      [
        "PBC178",
        "114 (49%)",
        "TE-LSM 7.6 kPa",
        "TE-LSM=0.92APRI=0.67FIB-4=0.63Forns=0.67",
        "TE-LSM+APRI= 0.92TE-LSM+FIB-4= 0.92TE-LSM+Forns= 0.92",
        "No increase in diagnostic accuracy for combination compared with TE-LSM alone"
      ],
      [
        "ALD162",
        "193 (40%)",
        "TE-LSM 12 kPa",
        "TE-LSM=0.90FT=0.85APRI=0.59FIB-4=0.63Forns=0.64",
        "TE-LSM+FT=0.91",
        "No increase in diagnostic accuracy for combination compared with TE-LSM alone"
      ],
      [
        "ALD161",
        "289 (23%)",
        "TE-LSM 15.5 kPa2D-SWE 16.4 kPa",
        "TE-LSM=0.892D-SWE=0.93ELF=0.92FT=0.88APRI=0.80FIB-4=0.85Forns=0.86",
        "TE-LSM+ELF=0.96—Other combinations not provided",
        "No difference in accuracy for TE-LSM in combination with blood-based markers (including ELF) compared with TE-LSM alone"
      ],
      [
        "Mixed CLD179CHC/CHB=40%HIV-HCV=22% ALD=13%NAFLD=11%",
        "1968 (34%)",
        "TE-LSM (N/A)",
        "TE-LSM=0.83-0.89FM=0.67-0.86",
        "TE-LSM+FM=0.85-0.92",
        "Higher AUC for combined tests for CHC"
      ]
    ],
    "row_count": 18,
    "column_count": 6
  },
  {
    "table_index": 15,
    "headers": [
      "References",
      "No. of biopsies (F2-4 prevalence)",
      "Elastography type and optimal LSM",
      "Single test AUC",
      "*Combined test AUC",
      "Comments"
    ],
    "rows": [
      [
        "HCV172",
        "183 (25%)",
        "TE-LSM 12.5 kPa",
        "TE-LSM=0.95FT=0.87APRI=0.83",
        "TE-LSM+APRI=0.95TE-LSM+FT=0.95TE-LSM+FT+APRI=0.95",
        "Agreement FT and TE-LSM=79%Biopsy confirmed F4=94%"
      ],
      [
        "HCV173",
        "729 (15%)",
        "TE-LSM (NA)",
        "TE-LSM=0.90FM=0.86",
        "TE-LSM+FM=0.92",
        "No difference in AUC for combination vs LSM alone"
      ],
      [
        "HCV141",
        "382 (15%)",
        "TE-LSM 12.9 kPa",
        "TE-LSM=0.93FM=0.90FT=0.87APRI=0.87ELF=0.87HS=0.89FIB-4=0.84",
        "Not provided",
        "Combination did not improve accuracy (93%) compared to single tests (86-92%)"
      ],
      [
        "HBV98",
        "92 (31%)",
        "ARFI 1.65 m/sTE-LSM 9.47 kPa",
        "ARFI=0.96TE-LSM=0.96APRI=0.85",
        "ARFI+TE-LSM+APRI=0.98",
        "No difference for linear combination over elastography alone"
      ],
      [
        "HBV174",
        "222 (53%)",
        "TE-LSM 7.6/812/13 kPa, for normal-elevated ALT",
        "TE-LSM=0.85ELF=0.71",
        "TE-LSM+ ELF- -Paired or sequential AUC and accuracy not provided.",
        "Sequential TE-LSM→ELF better than concurrent use for avoiding biopsy (61-65% vs 24-49%)"
      ],
      [
        "HIV-HCV143",
        "116 (11%)",
        "TE-LSM 12.5 kPa",
        "TE-LSM=0.92FT=0.78APRI=0.73",
        "AccuracyTE-LSM+FT=68.1%",
        "Synchronous algorithm. Lower correct classification (68.1%) compared to TE-LSM (85.3%) and FT (72.4%) alone"
      ],
      [
        "PBC177",
        "114 (15%)",
        "TE-LSM 11.4 kPa",
        "TE-LSM=0.99APRI=0.84FIB-4=0.74Forns=0.86",
        "TE-LSM+APRI=0.99TE-LSM+FIB-4=0.99TE-LSM+Forns=0.99",
        "No increase in diagnostic accuracy for combination"
      ],
      [
        "ALD162",
        "193 (15%)",
        "TE-LSM 15 kPa",
        "TE-LSM=0.93FT=0.88APRI=0.63FIB-4=0.80Forns=0.80",
        "TE-LSM+FT=0.94",
        "No increase in diagnostic accuracy for combination compared to TE-LSM alone"
      ],
      [
        "Mixed CLD178CHC/CHB=49%ALD=27%",
        "390 (31%)",
        "TE-LSM (NA)",
        "TE-LSM=0.92FM=0.83",
        "TE-LSM+FM=0.92",
        "Synchronous algorithm; no difference for combination vs LSM alone"
      ],
      [
        "Mixed CLD179CHC/CHB=40%HIV-HCV=22%ALD=13%NAFLD=11%",
        "1968 (18%)",
        "TE-LSM (NA)",
        "TE-LSM=0.90-0.95FM=0.73-0.92",
        "TE-LSM+FM=0.88-0.96",
        "Higher AUC for combined tests for CHC"
      ]
    ],
    "row_count": 10,
    "column_count": 6
  },
  {
    "table_index": 16,
    "headers": [
      "Author, year of study; assessed tool (reference)",
      "CLD and staging",
      "Biopsy N (follow-up n)",
      "Change in biopsy fibrosis",
      "NILDA change",
      "NILDA interval",
      "Comments/supporting evidence"
    ],
    "rows": [
      [
        "Schmid, 2015; TE-LSM144",
        "HIV-HCV F0-4(F4 in 13%)",
        "105",
        "10/42 (24%) progressed by≥1 stage",
        "LSM increased by 3.4 kPa in progressors (vs. −0.15 in nonprogressors)",
        "3 y",
        "LSM detected rapid progression in 2 subjects. Effect of antivirals not assessed (only 8 patients with SVR)"
      ],
      [
        "Pan, 2018; TE-LSM204",
        "HCV F≥3DAA-SVR(F4 in 67%)",
        "84 (15)",
        "12/15 (80%) regressed by≥1 stage",
        "LSM staging decreased in 62% (45% by≥2 stages)(59% from F4 and 68% from F3)",
        "Mean of 2 y",
        "Decline in collagen proportionate area from 7.1% to 38%Platelets increased significantly"
      ],
      [
        "Wong, 2011; TE-LSM205",
        "HBVNUC Rx(F4 in 11%)",
        "71 (71)",
        "11/71 (15%) progressed and 17/71 (24%) regressed by≥1 stage",
        "LSM changed by 0.4 kPa (−4.6 to 1.4) in progressors, by −2.7 kPa (−6.1 to −1.8) in regressors, and−1.7 kPa (−4.0 to 0) in static fibrosis",
        "1 y",
        "LSM changes weakly correlated with changes in histological fibrosis staging (Spearman’sr=0.25); potential confounding effect of ALT"
      ],
      [
        "Liang, 2018; TE-LSM206",
        "HBVNUC Rx(F3-4 in 32%)",
        "534 (164)",
        "98/164 (60%) regressed by≥1 stage",
        "LSM changed by −3.3 kPa in regressors, and by 0.3 kPa in progressors",
        "2 y",
        "Two improvement phases, initial at −2.2 kPa/24 week, paralleling ALT changes, and late at −0.3 kPa/24 week"
      ],
      [
        "Dong, 2019; TE-LSM76",
        "HBVNUC Rx(F3-4 in 21%)",
        "556 (182)",
        "72/182 regressed by≥1 stage",
        "LSM changed by −4.1 in regressors, and by −2.7 in progressors",
        "1.5 y",
        "The improvement in LSM correlated with improved inflammatory activity (r=0.395,p<0.001) and mildly with fibrosis (r=0.156,p=0.03)"
      ],
      [
        "Kong, 2019; TE-LSM207",
        "HBVNUC Rx(F4 in 17%)",
        "255 (212)",
        "86/212 (41%) regressed by≥1 stage",
        "LSM decreased by 43% in regressors vs. 32% in non-regressors",
        "1.5 y",
        "Steeper LSM decline among regressors vs. non-regressors (-2.19% per month;p<0.001) during initial 6 mo of treatment"
      ],
      [
        "Sun, 2019; TE-LSM208",
        "HBVNUC Rx(F4 in 4%)",
        "148 (148)",
        "53/148 (36%) regressed by≥1 stage",
        "Drop in LSM from 9.3±3.8 to 5.4±1.4 kPa (p<0.05)",
        "2 y",
        "LSM change in regressors or progressors was not reported. LSM did not predict regressed fibrosis, whereas high HBV DNA and METAVIR did"
      ],
      [
        "Wei, 2019; TE-LSM209",
        "HBVNUC Rx±p-IFN(All F2-F3)",
        "289 (141)",
        "39/141 (39%) regressed by≥1 stage",
        "LSM decreased from 8.7 kPa (6.7-13.7) to 5.8 (4.8-7.5) in regressors and 6.6 (5.4-8.9) in non-regressors",
        "1.5 y",
        "Along with AST, platelets, WBC, cholinesterase, ALT, and sex, LSM predicted fibrosis regression according to an artificial neural network model"
      ],
      [
        "Kamarajah, 2018; TE-LSM210",
        "NAFLD F0-4(F4 in 2%)",
        "113 (80)",
        "9/80 (11%) progressed and 19/80 (24%) regressed by≥1 stage",
        "LSM staging increased in 19% and decreased in 29%",
        "1 y",
        "LSM F3-4 without regression and F3-4 progressors had higher risk of adverse outcomes"
      ],
      [
        "Garg, 2018; TE-LSM211",
        "NAFLD(F3-4 in 15%)",
        "42 (32)",
        "3/32 (9%) progressed and 18/32 (56%) regressed by≥1 stage",
        "Drop in LSM from 8.6 (6.2-10.5) to 6 (4.2-8.9) kPa,p=0.003",
        "1 y",
        "Changed in LSM occurred early (third month) and there were significant drops in ALT, AST and BMITen patients did not consent for repeat liver biopsy"
      ],
      [
        "Nogami, 2019; TE-LSM212",
        "NAFLD F0-4(F4 in 12%)",
        "34 (14)",
        "2/14 (14%) regressed by≥1 stage",
        "LSM staging decreased in 32% and increased in 18%",
        "10 y",
        "Change in LSM correlated with fibrosis but not with inflammation or steatosis"
      ],
      [
        "Jayakumar, 2019; MRE213",
        "NAFLD 2-3(F3 in 63%)",
        "54 (54)",
        "8/54 (15%) progressed and 18/54 (33%) regressed by≥1 stage",
        "The AUROC was 0.57 (0.36-0.79) to detect progression of fibrosis and 0.79 (0.67-0.91) for regression",
        "0.5 y",
        "Poor correlation between MRE and baseline fibrosis stage (r=0.33) or CPA (r=0.19), but fair correlation with 24-week (r=0.55 andr=0.54, respectively)"
      ],
      [
        "Ajmera, 2020; MRE202",
        "NAFLDF0-4(F3-4 in 26%)",
        "102 (102)",
        "25% progressed and 28% regressed",
        "18% had an increase in LSM of≥15%",
        "1.4 y",
        "≥15% increase in LSM was strongest variable associated with rapid progression to advanced fibrosis (OR=3.36,p=0.03)"
      ],
      [
        "No baseline liver biopsy"
      ],
      [
        "Puente, 2019; TE-LSM214",
        "HCV F0-4DAA-SVR(F4 in 37%)",
        "271 (13)",
        "N/A",
        "LSM staging decreased in 34%",
        "2 y",
        "In 6/13 cases, LSM and biopsy stages coincided. LOXL2 levels lower if LSM<9 kPa"
      ],
      [
        "No follow-up liver biopsy"
      ],
      [
        "Stasi, 2013; TE-LSM215",
        "HCV F0-4IFN-based Rx(F4 in 23%)",
        "74 (21)",
        "N/A",
        "LSM dropped from 10.8±8.5 to 6.8±4.6 (p=0.01) in 30 patients with SVR",
        "3 y",
        "N/A"
      ],
      [
        "Enomoto, 2010; TE-LSM216",
        "HBV F0-4NUC Rx(F4 in 30%)",
        "50 (38)NUC in 20",
        "N/A",
        "LSM dropped from 11 (7-15) to 8 (5-12) in NUC-treated",
        "1 y",
        "Fair correlation between LSM and biopsy staging (r=0.46). LSM properly identified 1 regressor and 1 progressor of fibrosis (biopsy-proven)"
      ],
      [
        "Rinaldi, 2018; TE-LSM217",
        "HBV F0-4NUC Rx(F3-4 in 63%)",
        "200 (171)NUC in 149",
        "N/A",
        "LSM dropped from 14 to 8 in F3-F4 and from 7 to 5 in F0-2 among NUC-treated",
        "2 y",
        "No changes in LSM among untreated patients"
      ],
      [
        "No baseline NILDA"
      ],
      [
        "D’Ambrosio, 2013; TE-LSM218",
        "HCV F4IFN-based Rx SVR",
        "37 (37)",
        "20/37 (61%) regressed by≥1 stage",
        "LSM 9.1 kPa in regressed vs. 12.9 in nonregressed patients",
        "5 y",
        "Cirrhosis regression in 61%. Post-SVR LSM 61% sensitive and 95% specific to diagnose cirrhosis (threshold 12 kPa)"
      ]
    ],
    "row_count": 21,
    "column_count": 7
  },
  {
    "table_index": 17,
    "headers": [
      "Criteria",
      "Grayscale US",
      "CAP",
      "Noncontrast CT",
      "MRI-PDFF"
    ],
    "rows": [
      [
        "Objective",
        "Yes",
        "Yes",
        "Yes",
        "Yes"
      ],
      [
        "Subjective",
        "Yes",
        "No",
        "No",
        "No"
      ],
      [
        "Quantifiable (separation of steatosis grades)",
        "No",
        "No",
        "No",
        "Yes"
      ],
      [
        "Interobserver reliability",
        "Moderate",
        "Moderate",
        "High",
        "High"
      ],
      [
        "Sensitive to change (with therapy)",
        "No",
        "No",
        "No",
        "Yes"
      ],
      [
        "Used in clinical trials",
        "No",
        "No",
        "No",
        "Yes"
      ],
      [
        "Cost",
        "Low",
        "Low",
        "High",
        "High"
      ]
    ],
    "row_count": 7,
    "column_count": 5
  },
  {
    "table_index": 18,
    "headers": [
      "References",
      "Test",
      "Steatosis grade (by histology or MRI-PDFF)",
      "Cutoff (dB/m for CAP or % fat by MRI-PDFF)",
      "Sensitivity %",
      "Specificity %",
      "AUROC"
    ],
    "rows": [
      [
        "Sasso269",
        "CAP",
        "≥11%a",
        "238",
        "91",
        "81",
        "0.91"
      ],
      [
        "",
        "",
        "≥34%a",
        "259",
        "89",
        "86",
        "0.95"
      ],
      [
        "",
        "",
        "≥66%a",
        "292",
        "100",
        "78",
        "0.89"
      ],
      [
        "Friedrich-Rust293",
        "CAP",
        "≥33%a",
        "245",
        "97",
        "67",
        "0.78"
      ],
      [
        "",
        "",
        "≥66%a",
        "301",
        "76",
        "68",
        "0.72"
      ],
      [
        "Kumar294",
        "CAP",
        "≥33%a",
        "258",
        "78",
        "73",
        "0.79"
      ],
      [
        "",
        "",
        "≥66%a",
        "283",
        "71",
        "68",
        "0.77"
      ],
      [
        "de Lédinghen277",
        "CAP",
        "≥33%a",
        "310",
        "79",
        "71",
        "0.80"
      ],
      [
        "",
        "",
        "≥66%a",
        "311",
        "87",
        "47",
        "0.66"
      ],
      [
        "Imajo109",
        "CAPMR-PDFF",
        "≥5%a",
        "236",
        "82",
        "91",
        "0.88"
      ],
      [
        "",
        "",
        ">33%a",
        "270",
        "78",
        "80",
        "0.73"
      ],
      [
        "",
        "",
        ">66%a",
        "302",
        "64",
        "74",
        "0.70"
      ],
      [
        "",
        "",
        "≥5%",
        "5.2%",
        "90",
        "93",
        "0.96"
      ],
      [
        "",
        "",
        ">33%",
        "11.3%",
        "79",
        "84",
        "0.90"
      ],
      [
        "",
        "",
        ">66%",
        "17.1%",
        "74",
        "81",
        "0.79"
      ],
      [
        "Park110",
        "CAPMR-PDFF",
        "≥5%a",
        "261",
        "72",
        "86",
        "0.85"
      ],
      [
        "",
        "",
        ">33%b",
        "305",
        "63",
        "69",
        "0.70"
      ],
      [
        "",
        "",
        ">66%b",
        "312",
        "64",
        "70",
        "0.73"
      ],
      [
        "",
        "",
        "≥5%",
        "3.71",
        "96",
        "100",
        "0.99"
      ],
      [
        "",
        "",
        ">33%",
        "13.03",
        "80",
        "83",
        "0.90"
      ],
      [
        "",
        "",
        ">66%",
        "16.37",
        "82",
        "84",
        "0.92"
      ],
      [
        "Runge295",
        "CAPMR-PDFF",
        "≥5%a",
        "260",
        "90",
        "60",
        "0.77"
      ],
      [
        "",
        "",
        ">33%a",
        "296",
        "92",
        "55",
        "0.78"
      ],
      [
        "",
        "",
        ">66%a",
        "334",
        "78",
        "76",
        "0.78"
      ],
      [
        "",
        "",
        "≥5%",
        "4.14",
        "94",
        "100",
        "0.98"
      ],
      [
        "",
        "",
        ">33%",
        "15.72",
        "92",
        "97",
        "0.97"
      ],
      [
        "",
        "",
        ">66%",
        "20.88",
        "100",
        "83",
        "0.95"
      ],
      [
        "Chan283",
        "CAP",
        "≥5%a",
        "260",
        "91",
        "87",
        "0.94"
      ],
      [
        "",
        "",
        ">33%b",
        "266",
        "91",
        "87",
        "0.80"
      ],
      [
        "",
        "",
        ">66%b",
        "267",
        "100",
        "47",
        "0.69"
      ],
      [
        "Naveau296",
        "CAP",
        "≥5%b",
        "308",
        "68",
        "69",
        "0.85"
      ],
      [
        "",
        "",
        ">33%b",
        "335",
        "65",
        "79",
        "0.56"
      ],
      [
        "",
        "",
        ">66%b",
        "341",
        "74",
        "74",
        "0.36"
      ],
      [
        "Karlas297",
        "CAP",
        ">5%a",
        "215",
        "93",
        "87",
        "0.93"
      ],
      [
        "",
        "",
        ">33%a",
        "268",
        "97",
        "81",
        "0.94"
      ],
      [
        "",
        "",
        ">66%a",
        "300",
        "82",
        "76",
        "0.82"
      ],
      [
        "Myers287",
        "CAP",
        ">11%a",
        "289",
        "68",
        "88",
        "0.73"
      ],
      [
        "",
        "",
        ">33%a",
        "288",
        "85",
        "62",
        "0.68"
      ],
      [
        "",
        "",
        ">66%a",
        "283",
        "94",
        "47",
        "0.52"
      ],
      [
        "Sasso270",
        "CAP",
        ">11%a",
        "222",
        "76",
        "71",
        "0.80"
      ],
      [
        "",
        "",
        ">33%a",
        "233",
        "87",
        "74",
        "0.86"
      ],
      [
        "",
        "",
        ">66%a",
        "290",
        "78",
        "93",
        "0.88"
      ],
      [
        "Jung275",
        "CAP",
        "≥5%a",
        "250",
        "69",
        "93",
        "0.86"
      ],
      [
        "",
        "",
        ">33%a",
        "301",
        "82",
        "88",
        "0.90"
      ],
      [
        "",
        "",
        ">66%a",
        "325",
        "50",
        "81",
        "0.74"
      ],
      [
        "Shen274",
        "CAP",
        "≥5%a",
        "253",
        "89",
        "82",
        "0.92"
      ],
      [
        "",
        "",
        ">33%a",
        "285",
        "93",
        "83",
        "0.92"
      ],
      [
        "",
        "",
        ">66%a",
        "310",
        "92",
        "79",
        "0.88"
      ],
      [
        "Lupsor-Planton298",
        "CAP",
        "≥5%a",
        "260",
        "65",
        "87",
        "0.81"
      ],
      [
        "",
        "",
        ">33%a",
        "285",
        "70",
        "85",
        "0.82"
      ],
      [
        "",
        "",
        ">66%a",
        "294",
        "83",
        "82",
        "0.84"
      ],
      [
        "Wong291",
        "CAP",
        "≥5%a",
        "222",
        "87",
        "62",
        "0.85"
      ],
      [
        "",
        "",
        "",
        "290",
        "60",
        "90",
        ""
      ],
      [
        "Jun290",
        "CAP",
        "≥5%a",
        "247",
        "92",
        "86",
        "0.90"
      ],
      [
        "",
        "",
        "",
        "300",
        "51",
        "100",
        "0.74"
      ],
      [
        "Lee299",
        "CAP",
        "≥5%a",
        "247",
        "88",
        "100",
        "0.95"
      ],
      [
        "",
        "",
        ">33%a",
        "280",
        "85",
        "80",
        "0.85"
      ],
      [
        "",
        "",
        ">66%a",
        "300",
        "73",
        "61",
        "0.73"
      ],
      [
        "Chon276",
        "CAP",
        "≥5%a",
        "250",
        "73",
        "95",
        "0.88"
      ],
      [
        "",
        "",
        ">33%a",
        "299",
        "82",
        "86",
        "0.89"
      ],
      [
        "",
        "",
        ">66%a",
        "327",
        "79",
        "84",
        "0.80"
      ],
      [
        "Price300",
        "CAP",
        "≥5%a",
        "238",
        "84",
        "75",
        "0.85"
      ],
      [
        "Garg211",
        "CAP",
        "≥5%b",
        "323",
        "59",
        "83",
        "0.75"
      ],
      [
        "",
        "",
        ">33%b",
        "336",
        "74",
        "75",
        "0.74"
      ],
      [
        "",
        "",
        ">66%b",
        "357",
        "100",
        "78",
        "0.82"
      ],
      [
        "Andrade281",
        "CAP",
        ">5%a",
        "206",
        "82",
        "76",
        "0.82"
      ],
      [
        "",
        "",
        ">33%a",
        "232",
        "93",
        "84",
        "0.96"
      ],
      [
        "",
        "",
        ">66%a",
        "282",
        "95",
        "89",
        "0.97"
      ],
      [
        "Mendes292",
        "CAP",
        ">5%a",
        "248",
        "92",
        "83",
        "0.86"
      ],
      [
        "",
        "",
        ">33%a",
        "268",
        "81",
        "99",
        "0.94"
      ],
      [
        "",
        "",
        ">66%a",
        "280",
        "84",
        "99",
        "0.96"
      ],
      [
        "Darweesh301",
        "CAP",
        ">5%a",
        "297",
        "81",
        "73",
        "0.77"
      ],
      [
        "",
        "",
        ">33%a",
        "366",
        "85",
        "96",
        "0.92"
      ],
      [
        "Eddowes278",
        "CAP",
        ">5%ab",
        "302",
        "80",
        "83",
        "0.87"
      ],
      [
        "",
        "",
        ">33%ab",
        "331",
        "70",
        "76",
        "0.77"
      ],
      [
        "",
        "",
        ">66%ab",
        "337",
        "72",
        "63",
        "0.70"
      ],
      [
        "de Lédinghen302",
        "CAP",
        ">5%ab",
        "246/242",
        "75/75",
        "75/75",
        "0.82/0.83"
      ],
      [
        "",
        "",
        ">33%ab",
        "269/267",
        "80/80",
        "81/81",
        "0.89/0.88"
      ],
      [
        "",
        "",
        ">66%ab",
        "285/286",
        "81/84",
        "81/84",
        "0.92/0.93"
      ],
      [
        "Siddiqui303",
        "CAP",
        "≥5%a",
        "285c",
        "80",
        "77",
        "0.76"
      ],
      [
        "",
        "",
        ">33%b",
        "263",
        "90",
        "35",
        "0.70"
      ],
      [
        "",
        "",
        ">66%b",
        "353",
        "29",
        "90",
        "0.58"
      ],
      [
        "",
        "",
        "",
        "311c",
        "77",
        "57",
        ""
      ],
      [
        "",
        "",
        "",
        "280",
        "90",
        "35",
        ""
      ],
      [
        "",
        "",
        "",
        "367",
        "20",
        "90",
        ""
      ],
      [
        "",
        "",
        "",
        "306c",
        "80",
        "40",
        ""
      ],
      [
        "",
        "",
        "",
        "274",
        "90",
        "20",
        ""
      ],
      [
        "",
        "",
        "",
        "380",
        "3",
        "90",
        ""
      ],
      [
        "Chan304",
        "CAP",
        "≥5%ab",
        "253/279",
        "93/83",
        "71/88",
        "0.84/0.91"
      ],
      [
        "",
        "",
        "≥33%ab",
        "294/303",
        "85/79",
        "59/65",
        "0.76/0.78"
      ],
      [
        "",
        "",
        "≥66%ab",
        "294/325",
        "88/76",
        "36/54",
        "0.61/0.65"
      ],
      [
        "Caussy246",
        "CAP",
        "≥5%",
        "288",
        "75",
        "77",
        "0.80"
      ],
      [
        "",
        "",
        "≥10%",
        "306",
        "79",
        "82",
        "0.87"
      ],
      [
        "Xu305",
        "CAP",
        "≥5%a",
        "224",
        "69",
        "76",
        "0.78"
      ],
      [
        "",
        "",
        "≥33%a",
        "246",
        "100",
        "78",
        "0.93"
      ],
      [
        "",
        "",
        "≥66%a",
        "284",
        "100",
        "96",
        "0.99"
      ],
      [
        "Ooi306",
        "CAP",
        "≥33%a",
        "285",
        "85",
        "47",
        "0.69"
      ],
      [
        "Caussy307",
        "CAP",
        "≥5%a",
        "294/261/316",
        "75/90/59",
        "78/50/90",
        "0.83"
      ],
      [
        "",
        "",
        "≥5%b",
        "307/281/323",
        "73/90/62",
        "75/65/90",
        "0.858"
      ],
      [
        "",
        "",
        "≥10%a",
        "311//293/326",
        "79/90/58",
        "85/71/90",
        "0.88"
      ],
      [
        "",
        "",
        "≥10%b",
        "322/314/323",
        "83/90/83",
        "65/83/90",
        "0.93"
      ],
      [
        "Ferraioli263",
        "CAP",
        "≥5%a",
        "273c",
        "80",
        "83",
        "0.85"
      ],
      [
        "Petroff308",
        "CAPb",
        "≥5%",
        "294/263c/354c",
        "79/90/52",
        "74/50/90",
        "0.81"
      ],
      [
        "",
        "",
        "≥33%",
        "310/286c/372c",
        "79/90/25",
        "59/39/90",
        "0.73"
      ],
      [
        "",
        "",
        "≥66%",
        "331/297c/385",
        "72/90/22",
        "62/34/90",
        "0.71"
      ],
      [
        "Beyer309",
        "CAP",
        "≥5%",
        "269c",
        "89",
        "100",
        "0.95"
      ],
      [
        "",
        "",
        "≥33%",
        "308c",
        "78",
        "41",
        "0.60"
      ],
      [
        "",
        "",
        "≥66%",
        "337c",
        "61",
        "59",
        "0.63"
      ],
      [
        "Audière310",
        "CAP",
        "≥5%",
        "273c",
        "",
        "",
        "0.89"
      ],
      [
        "Garteiser311",
        "CAP",
        "≥5%",
        "316c",
        "79",
        "84",
        "0.83"
      ],
      [
        "",
        "",
        "≥33%",
        "316c",
        "87",
        "61",
        "0.79"
      ],
      [
        "",
        "",
        "≥66%",
        "343c",
        "77",
        "64",
        "0.73"
      ],
      [
        "Yen312",
        "CAP",
        "10%-30%",
        "257c",
        "100",
        "89",
        "0.96"
      ],
      [
        "Zhuang313",
        "CAP",
        "≥5%",
        "270c",
        "100",
        "83",
        "0.94"
      ],
      [
        "Duarte-Rojo56",
        "CAP",
        "≥34%",
        "230c",
        "100",
        "53",
        "0.79"
      ],
      [
        "Siddiqui87",
        "CAP",
        "≥5%",
        "270c",
        "74",
        "87",
        "0.88"
      ],
      [
        "",
        "",
        "≥34%",
        "295c",
        "100",
        "89",
        "0.94"
      ],
      [
        "",
        "",
        "≥67%",
        "295c",
        "100",
        "84",
        "0.89"
      ]
    ],
    "row_count": 118,
    "column_count": 7
  },
  {
    "table_index": 19,
    "headers": [
      "References",
      "Imaging NILDA",
      "Pediatric liver disease",
      "AUROC (sensitivity/specificity %) and correlation when available",
      "Correlation with fibrosis (r)",
      "Biopsy measure",
      "Comments"
    ],
    "rows": [
      [
        "Shin318",
        "VCTE",
        "BA (n=47)",
        "0.86 for F3(89.5%/75%)0.96 for F4(100%/90.5%)",
        "0.63",
        "METAVIR fibrosis",
        "All were pre-Kasai hepatoportoenterostomyCutoff for F3: 9.6 kPaCutoff for F4: 18.1 kPaSuccess rate with the pediatric S probe (100%) vs M probe (77%;p<0.001)"
      ],
      [
        "Hukkinen311",
        "VCTE",
        "BA (n=39)",
        "0.82 for F4(76%/75%)",
        "0.48",
        "METAVIR fibrosis",
        "All were s/p KasaiCutoff for F4: 23.8 kPaAUROC increased with age"
      ],
      [
        "Gao320",
        "ARFI",
        "BA (n=50)",
        "0.82 for F≥2(91.4%/61.5%)0.88 for F≥3(94.7%/74.2%)0.92 for F=4(87.5%/90.5%)",
        "0.72",
        "Batts-Ludwig fibrosis",
        "All were pre-Kasai.Cutoff for F≥2: 1.53 m/sCutoff for F≥3: 1.80 m/sCutoff for F=4: 2.16 m/s"
      ],
      [
        "Chen321",
        "SSWE",
        "BA (n=24)",
        "0.79 for F≥2(80%/73.7%)0.81 for F≥3(77.8%/80%)0.82 for F4(93.8%/87.5%)",
        "0.76",
        "METAVIR fibrosis",
        "All were s/p KasaiCutoff for F2: 9.4 kPaCutoff for F3: 10.8 kPaCutoff for F4: 24.4 kPa"
      ],
      [
        "Lewindon322",
        "VCTE",
        "CFLD (n=22)",
        "0.87 for F3-4(75%/100%)",
        "0.67",
        "METAVIR fibrosis",
        "Cutoff for F3-4: 8.7 kPa"
      ],
      [
        "Garcovich323",
        "SWE",
        "NASH (n=68)",
        "0.92 for≥F1(85%/95%)0.97 for≥F2(87%/96%)",
        "0.84",
        "Brunt fibrosis",
        "Brunt classification (0-4)Cutoff for F≥1: 5.1 kPaCutoff for F≥2: 6.7 kPa"
      ],
      [
        "Middleton243",
        "MRI-PDFF",
        "NAFLD (n=83)",
        "0.87 for S1 vs S2-3(74%/90%)0.79 for s-2 vs S3(60%/90%)",
        "",
        "NASH CRNSteatosis (1-3)",
        "Cutoff for S2-3: 17.5%Cutoff for S3: 23.3%"
      ],
      [
        "Schwimmer324",
        "MRE",
        "NAFLD (n=90)",
        "0.77 for≥F1a(44.4%/90.7%)0.89 for≥F3a(33.3%/90.5%)",
        "0.53b",
        "NASH CRNFibrosis (0-4)",
        "Cutoff for≥F1: 2.78 kPa+Cutoff for≥F3: 3.33 kPa+"
      ],
      [
        "Behairy325",
        "VCTE",
        "HCV (n=50)",
        "0.70 for≥F10.87 for≥F20.80 for≥F3",
        "0.56",
        "Ishak fibrosis",
        "Cutoffs not available"
      ],
      [
        "Awad327",
        "VCTE",
        "HCV (n=30)",
        "1.0 for F40.82 for F3",
        "0.77",
        "METAVIR fibrosis",
        "Cutoff for F3: 9.5 kPaCutoff for F4: 12.5 kPa"
      ]
    ],
    "row_count": 10,
    "column_count": 7
  },
  {
    "table_index": 20,
    "headers": [],
    "rows": [
      [
        "Studies on NILDA should include diverse populations."
      ],
      [
        "Comparative studies combining both blood-based and imaging-based tests performed synchronously and sequentially are needed to match clinical practice, with recognition of test utility by insurance and third-party payors."
      ],
      [
        "Prospective data on the diagnostic utility of simple and proprietary blood tests compared to imaging are needed. Ideally, validation studies should include paired comparisons with both imaging-based and blood-based tests from the same individual compared against liver histology (or if assessing fat, with histology or MRI-PDFF as reference)."
      ],
      [
        "Further define the role of imaging-based NILDA in treated patients with HCV and HBV."
      ],
      [
        "Define the performance and threshold of imaging-based NILDA in MASLD."
      ],
      [
        "Additional studies are needed to further develop the assessment of hepatic inflammation either via US (i.e., use of shear wave dispersion slope)356or with alternative MRI methods (i.e., multiparametric iron-corrected T1 mapping [cT1]).357"
      ],
      [
        "Regarding steatosis, additional studies comparing sonographic liver attenuation tools are needed, along with their potential combination in screening algorithms with blood-based NILDA. The role of US-based and MRI-PDFF/MRS to monitor changes in steatosis with therapies also merits further study."
      ],
      [
        "The diagnosis of NASH (not just fibrosis in NAFLD) represents a particular challenge for NILD,358,359and there is need for further study. Emerging MRE techniques, such as 3D MRER360and multifrequency acquisition,236,361show promising results in NASH and should be further evaluated."
      ],
      [
        "In light of these emerging data and the fact that NAFLD will soon become the primary indication for liver transplantation in adults, a reliable and validated method for detecting and quantifying steatosis in children to prevent sequelae in adulthood should be a priority."
      ],
      [
        "Utilization of artificial intelligence and machine learning should allow for incorporation of demographics and a wide array of clinical data including genome-wide association studies, microbiome, and metabolomic tests to improve diagnosis and management of CLD."
      ],
      [
        "Research is needed on the generalizability of NILDA, including simplified algorithms across imaging-based modalities and expanded initiatives to further standardize LSM acquisition and quality reporting across manufacturers and across different disease etiologies, if needed."
      ],
      [
        "Study of novel approaches to reduce hardware/software costs necessary for widespread implementation of advanced imaging techniques is needed."
      ],
      [
        "Longitudinal studies of NILDA to assess the natural history of a disease, clinical outcomes, and changes with therapy are needed."
      ],
      [
        "Quantitative techniques and protocols for sequential use of NILDA for following fibrosis regression are needed. These could help better reflect scar regression given the ceiling effect (i.e., unique F4 stage irrespective of fibrosis thickness) imposed by standard pathology, which is not observed with collagen histomorphometry."
      ],
      [
        "Cost-effectiveness analysis studies will help determine appropriateness criteria of blood tests vs. imaging tests for fibrosis and/or steatosis detection in varied clinical scenarios (e.g., general population screening vs. at-risk populations)."
      ]
    ],
    "row_count": 15,
    "column_count": 1
  }
]